Pharvaris stock price target lowered to $52 by Citizens JMP

Pharvaris (NASDAQ:PHVS) is nearing a pivotal moment as Phase 3 data for its hereditary angioedema (HAE) treatment, deucrictibant, is anticipated next quarter, following positive efficacy results from the RAPIDe-2 study. While Citizens JMP maintains a Market Outperform rating with a $52 price target, projecting combined peak sales of $2.2 billion across HAE and acquired angioedema (AAE) indications, BofA Securities reiterates an Underperform rating with a $14 target, reflecting divergent analyst views ahead of the key data readout. The company, which holds a strong financial position, recently announced a $175 million public offering to fund its angioedema programs, positioning it to compete against KalVista's Ekterly in the HAE market.

Analysis

Pharvaris (NASDAQ:PHVS) is approaching a significant catalyst with the anticipated release of Phase 3 data for its hereditary angioedema (HAE) drug, deucrictibant, next quarter. Analyst sentiment is sharply divided, creating a high-risk, high-reward scenario. Citizens JMP maintains a Market Outperform rating, lowering its price target to $52 but projecting substantial peak sales of $2.2 billion combined for acute and prophylactic HAE indications, with further upside from a potential expansion into acquired angioedema (AAE). Conversely, BofA Securities reiterates an Underperform rating with a $14 price target, underscoring the binary nature of the upcoming clinical trial results. The company's financial position appears robust, evidenced by a balance sheet with more cash than debt, a current ratio of 11.1, and a recent public offering poised to raise approximately $175 million to fund its programs. This financial stability is crucial as it prepares to compete with KalVista’s recently launched Ekterly, with the comparative efficacy data from the RAPIDe-3 study being a key determinant of future market share.

Key Decisions for Investors

• Investors should recognize that Pharvaris presents a binary investment case heavily dependent on the outcome of its Phase 3 deucrictibant data expected next quarter.
• Consider the starkly divergent analyst outlooks, with Citizens JMP's $52 target suggesting significant upside on positive data, while BofA's $14 target highlights substantial downside risk on trial failure.
• While the company's balance sheet is fortified by a recent $175 million capital raise, long-term value hinges on deucrictibant's ability to compete effectively with KalVista's Ekterly, making the comparative trial data a critical factor to monitor.
• It may be prudent to monitor the initial market uptake and physician feedback for KalVista’s Ekterly, as this provides a real-time proxy for the commercial potential of the on-demand HAE market.